Adagene to present new ADG126 clinical data at ASCO-GI

Investors and interested parties are advised that the forward-looking statements in this announcement are subject to various factors that could cause actual results to differ materially from those anticipated. These factors include the completion of clinical development, regulatory milestones, commercialization of product candidates, intellectual property protection, and potential impact of the COVID-19 pandemic on operations. The stock has experienced significant volatility, with a year-to-date return of -7.54% and revenue of $0.82 million in the last twelve months. For deeper insights into Adagene's financial health and 12+ additional ProTips, visit InvestingPro. The stock has experienced significant volatility, with a year-to-date return of -7.54% and revenue of $0.82 million in the last twelve months. For deeper insights into Adagene's financial health and 12+ additional ProTips, visit InvestingPro. The data presentation, scheduled for January 25, 2025, will highlight results from a combination study of ADG126 with Merck (NSE:PROR)'s KEYTRUDA® in MSS CRC.

Investors and interested parties are advised that the forward-looking statements in this announcement are subject to various factors that could cause actual results to differ materially from those anticipated. These factors include the completion of clinical development, regulatory milestones, commercialization of product candidates, intellectual property protection, and potential impact of the COVID-19 pandemic on operations. The stock has experienced significant volatility, with a year-to-date return of -7.54% and revenue of $0.82 million in the last twelve months. For deeper insights into Adagene's financial health and 12+ additional ProTips, visit InvestingPro.

ADG126, also known as muzastotug, is a novel anti-CTLA-4 SAFEbody® developed by Adagene. It is designed to minimize on-target off-tumor toxicity by using precision masking technology, which allows for tumor-specific targeting of antibodies within the tumor microenvironment.

The symposium presentation will take place at the Moscone West in San Francisco, with details available on the company's website following the event. Additionally, Adagene will host a virtual key opinion leader (KOL) event on the same day, featuring discussions by prominent medical experts on the treatment landscape for advanced/metastatic MSS CRC and the significance of CTLA-4 targeting in this context.

This announcement is based on a press release statement and follows Adagene's commitment to developing innovative antibody-based cancer immunotherapies. The company leverages computational biology and artificial intelligence in its Dynamic Precision Library platform to create differentiated immunotherapy programs.

Adagene's strategic collaborations with global partners aim to address unmet patient needs through its SAFEbody® technology. The company's lead clinical program, ADG126, targets regulatory T cells in the tumor microenvironment and is part of ongoing research to establish its safety and efficacy.

Investors and interested parties are advised that the forward-looking statements in this announcement are subject to various factors that could cause actual results to differ materially from those anticipated. These factors include the completion of clinical development, regulatory milestones, commercialization of product candidates, intellectual property protection, and potential impact of the COVID-19 pandemic on operations.

In other recent news, Adagene Inc. has faced a downgrade from Jefferies, shifting the stock rating from Buy to Hold with a reduced price target of $3.50. This decision follows observations of Adagene's ADG126, an anti-CTLA-4 therapy, which has shown promising activities, but its efficacy appears more pronounced in a specific patient subset, excluding those with liver and peritoneal metastases. Jefferies' downgrade is further influenced by questions around the regulatory development pathway for ADG126, pushing the expected commercial launch date from 2028 to 2029.

In spite of the downgrade, analysts from H.C. Wainwright have maintained a Buy rating on Adagene, reinforcing confidence in ADG126's potential. They consider the stock undervalued given the promising results and the company's current market capitalization of approximately $100 million.

These recent developments follow Adagene's significant findings presented at the Society for Immunotherapy of Cancer (SITC) and the European Society of Medical (TASE:PMCN) Oncology (ESMO) Congress. The research focused on its proprietary SAFEbody® technology platform, specifically the anti-CTLA-4 antibody, ADG126. Furthermore, the combination of ADG126 with pembrolizumab showed a confirmed overall response rate of 24% and a disease control rate of 88% in recent studies, underscoring Adagene's commitment to developing innovative treatments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.